Recent news on Steris Plc. (STE) shows a mix of both positive and negative signals. On one hand, reports of strong fiscal Q3 and Q4 2024 results, with revenue and earnings growth, have been positively received. Analysts have also given a Moderate Buy consensus rating to the company's stock. Notwithstanding, there are concerns over insider sales, with SVP and President, Healthcare Cary Majors, and director Jacqueline B. Kosecoff selling shares. In addition, Steris's stock has been found underperforming its competitors on some trading days. It has also matched Q4 earnings estimates, despite experiencing contraction in margins. Investors are advised to perform additional checks before purchasing shares for its next dividend. Steris has also shed off its dental segment for nearly $800 million, a development that will influence future earnings. The company's stock position has been decreased by several advisory and investment firms including Dimensional Fund Advisors LP, Swiss National Bank, and Russell Investments Group Ltd. but acquired by others like Spire Wealth Management, Principal Securities Inc., and Quotient Wealth Partners LLC among others.
Steris Plc STE News Analytics from Thu, 30 Aug 2018 07:00:00 GMT to Sat, 18 May 2024 21:43:31 GMT - Rating 0 - Innovation 8 - Information 8 - Rumor -5
